SVF
Level D· Preclinical EvidenceAnimal Study

Alpha-1-Antitrypsin Enhances Fat Graft Survival in a Murine Model.

Halpern D., Farber I., Anav Y., Tsitrina A., Lewis EC., Silberstein E.

Animal Study with a reported sample of 8 on Chronic Wound, published in Adv Wound Care (New Rochelle) (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Wound Care (New Rochelle) (2026)
Country
United States
Reported sample size
8
PMID
40105893
DOI
10.1089/wound.2024.0176

Abstract (original English)

Fat grafting is widely applied for various purposes, including volume restoration, improving tissue quality, and promoting wound healing, but it has poor long-term graft survival predictability. Alpha-1-antitrypsin (AAT) administration is hypothesized to improve fat graft outcomes by expediting inflammatory resolution and graft vascularity and reducing necrosis. Mice heterozygote to human AAT was grafted fat under the scalp alongside 400 µg/graft AAT or albumin (ALB) on days 0 and 3. Graft volume was determined by micro-magnetic resonance imaging, and explants were assessed for viability, histology, immunohistochemistry, and expression of selected genes. AAT expression was examined in hypoxia-exposed adipose-derived stem cells (ADSCs). After 90 days, AAT-treated grafts maintained higher volumes (70.06% vs. 34.54%, n = 8, p = 0.02) and displayed improved tissue quality. On day 10 after grafting, grafts exhibited more blood vessels (mean 1.94/mm 2 vs. 0.33/mm 2 ) and 6.25-fold more adiponectin transcript levels ( n = 12, p = 0.02). Although day-3 interleukin (IL)-1β expression was 5-fold greater in AAT-treated grafts ( n = 6, p = 0.4), day-10 IL-1β expression was 2-fold lower compared to ALB-treated grafts ( n = 22, p = 0.01). In the Methoxynitrosulfophenyl-tetrazolium carboxanilide (XTT) assay, day-3 AAT-treated grafts were 1.56-fold more metabolically functional ( n = 6, p = 0.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Animalsalpha 1-AntitrypsinMiceGraft SurvivalAdipose TissueWound HealingMice, Inbred C57BLDisease Models, AnimalMaleModels, Animal
Chronic Wound
View on PubMedDOI

Related research